Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF)supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy

Lane, Steven W., Crawford, Julie, Kenealy, Melita, Cull, Gavin, Seymour, John F., Prince, H. Miles, Marlton, Paula, Gill, Devinder ‌ and Mollee, Peter‌ N. (2006) Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF)supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy. Leukemia and Lymphoma, 47 9: 1813-1817. doi:10.1080/10428190600632832


Author Lane, Steven W.
Crawford, Julie
Kenealy, Melita
Cull, Gavin
Seymour, John F.
Prince, H. Miles
Marlton, Paula
Gill, Devinder ‌
Mollee, Peter‌ N.
Title Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF)supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy
Journal name Leukemia and Lymphoma   Check publisher's open access policy
ISSN 1042-8194
1029-2403
Publication date 2006-09
Sub-type Article (original research)
DOI 10.1080/10428190600632832
Volume 47
Issue 9
Start page 1813
End page 1817
Total pages 5
Place of publication Chur, New York
Publisher Harwood Academic Publishers
Language eng
Subject 1112 Oncology and Carcinogenesis
Abstract Pegfilgrastim (Neulasta®) has proven efficacy as supportive therapy in a variety of 21-day chemotherapy regimens, but has not been studied in dose intensive, rapidly cycling regimens utilising cell-cycle active drugs (e.g. anti-metabolites) such as hyper-CVAD. This study examined whether pegfilgrastim was safe and lead to similar kinetics of neutrophil recovery as daily granulocyte colony stimulating factor (G-CSF). Using retrospective analysis, patients receiving pegfilgrastim (6 mg) were matched with controls (G-CSF 5 μg kg-1 per day) for a cycle of chemotherapy, prior chemotherapy, dose of cytarabine received, age (<60 or >60 years), diagnosis and bone marrow involvement. The primary endpoint was duration of grade IV neutropenia (absolute neutrophil count, ANC < 500 μl-1). Secondary endpoints included time to neutrophil recovery, incidence of febrile neutropenia, positive blood cultures and delay in subsequent chemotherapy. This study identified 124 pegfilgrastim supported cycles in 43 patients and successfully matched them to 124 G-CSF supported cycles from 38 patients treated between January 1999 and July 2005. There were no significant differences between pegfilgrastim and G-CSF groups in baseline or treatment-related variables. The median duration of grade IV neutropenia was 4 days in both groups (P = 0.55). Time to neutrophil recovery, incidence of febrile neutropenia, positive blood cultures and delay in subsequent chemotherapy were similar in both groups. Once per cycle dosing of pegfilgrastim appears safe and as effective as daily G-CSF for supporting the hyper-CVAD chemotherapy regimen.
Keyword pegfilgrastim
G-CSF
hyper-CVAD
neutropenia
lymphoid malignancy
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 11 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 13 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 31 Mar 2009, 14:23:35 EST by Ms Sarada Rao on behalf of Faculty Of Health Sciences